Can Women Take the Same Peptides as Men?

By NorthPeptide Research Team  |  May 7, 2026

The Short Answer

Yes — for the vast majority of research peptides, women can use the same compounds as men. Most peptides target biological systems that both sexes share: gut lining, collagen synthesis, tissue repair, appetite signaling, immune function. There is nothing inherently male-specific about any of those mechanisms.

That said, “the same” does not always mean “identical effects.” Some peptides show different response profiles between the sexes. A few require different dosing in research protocols. And there are specific situations — pregnancy and breastfeeding being the clearest — where no peptides should be used regardless of sex.

Here is what the research actually shows, category by category.

GLP-1 Peptides: Women Were the Majority in Clinical Trials

The biggest misconception in peptide research is that GLP-1 agonists are somehow “men’s compounds.” The opposite is closer to the truth. Women made up 74–81% of participants across the STEP trials for semaglutide. These were not small studies — STEP 1 alone enrolled 1,961 participants.

The efficacy data in women is strong and, in some respects, stronger than in men:

• Semaglutide (STEP trials): Women lost an average of 14.0% body weight compared to 8.0% in men in the semaglutide group of the STEP 1 trial. While some of this difference may reflect baseline differences in body composition and starting BMI, the efficacy signal in women is clear (PMC9981825).
• Tirzepatide (SURMOUNT trials): A post-hoc analysis found that tirzepatide produced significant weight reduction in women regardless of reproductive stage — premenopausal, perimenopausal, and postmenopausal women all showed meaningful responses (PMC12015656).
• Retatrutide: Phase 2 trial data enrolled both sexes, and there is no evidence from published data of sex-specific efficacy differences.

Side Effect Profile in Women

One honest caveat: women appear to report GLP-1 side effects more frequently than men. An analysis of adverse event reports found approximately 73% of reported semaglutide side effects came from women (PMC12033487). The most common effects — nausea, constipation, reduced appetite — are identical between sexes, but the frequency of reporting differs. Whether this reflects true biological difference or reporting behavior differences is unclear.

BPC-157 and TB-500: Tissue Repair Is Not Sex-Dependent

BPC-157 and TB-500 are the two primary research peptides focused on tissue repair. Their core mechanisms — promoting cell migration, stimulating angiogenesis, modulating the nitric oxide system, upregulating growth factor receptors — operate identically in male and female biology.

The animal research for BPC-157 has been conducted in both male and female rat models without sex-specific findings (PMC7096228). The same applies to thymosin beta-4 / TB-500 research (PMC8228050).

There are no known sex-specific concerns for either compound based on available preclinical literature.

GH Secretagogues: Awareness of the Estrogen-GH Axis Matters

Growth hormone secretagogues — including sermorelin, CJC-1295, ipamorelin, GHRP-2, and GHRP-6 — stimulate the pituitary gland to produce and release endogenous growth hormone. They are not sex-specific in mechanism.

However, women and men have meaningfully different baseline GH secretion patterns, and this context matters for interpreting research outcomes:

• Women produce GH in a more continuous, steady pattern, while men produce it in sharper, higher-amplitude pulses (PMC2699646).
• Estrogen amplifies GH secretion — premenopausal women produce more GH than men of the same age (PMC3765363). This means GH secretagogues are being applied against a higher baseline in most premenopausal female research subjects.
• After menopause, women’s GH secretion drops significantly. Postmenopausal women may show different responses to GH secretagogues than premenopausal women.

None of this makes GH secretagogues unsafe for women — it simply means that interpreting results requires accounting for the hormonal context. Research protocols studying GH secretagogues in women should include baseline GH measurements and should stratify by reproductive stage where possible.

Melanotan II and PT-141: Different Response Profiles

PT-141 (bremelanotide) is one of the few research peptides where sex-specific data is both extensive and clinically meaningful. It has been studied for sexual dysfunction in both men and women, and the findings differ significantly.

In men, PT-141 primarily works by inducing erections through central melanocortin receptor activation — a non-vascular mechanism different from PDE5 inhibitors like sildenafil.

In women, PT-141 has been studied for hypoactive sexual desire disorder (HSDD). The FDA-approved drug Vyleesi (bremelanotide 1.75 mg injectable) is specifically indicated for premenopausal women with HSDD — making it one of the rare peptide-derived compounds with an approved indication specifically in women.

The key differences:

• Dosing: Clinical trials in women used lower doses than those used in male studies. The approved female dosing (1.75 mg) should be referenced when designing female-focused research protocols.
• Response mechanism: Women showed improvements in desire and reduced distress related to sexual activity — a different set of endpoints than the primarily erectile-focused outcomes in male studies (PMC6713510).
• Side effects: Nausea is more common in women than in male study populations, particularly at higher doses.

Melanotan II, the older and less selective melanocortin agonist, has not been studied with the same rigor. It affects tanning, appetite suppression, and sexual function simultaneously, and its indiscriminate receptor activity makes sex-specific effects harder to isolate. It should be treated with appropriate caution in research design.

Pregnancy and Breastfeeding: A Clear Line

This guidance applies regardless of the specific peptide: no research peptides during pregnancy or breastfeeding.

The reason is not that peptides are known to be harmful during pregnancy — it is that no peptides have been adequately studied in pregnant populations, and the risk-benefit calculation in the absence of data defaults firmly to caution. For GLP-1 agonists specifically, prescribing guidelines recommend discontinuing treatment at least two months before a planned pregnancy (PMC11649328).

For breastfeeding, GLP-1 molecules are large proteins unlikely to transfer meaningfully into breast milk based on molecular weight, but the human data does not exist to confirm safety, so avoidance is the appropriate position.

Dosing Differences: What the Evidence Shows

For most peptides, dosing protocols in published research do not differ by sex. The compounds where dosing awareness is most relevant:

Peptide	Sex-Specific Notes
PT-141	FDA-approved female dose (1.75 mg) is standardized. Male research protocols use different dose ranges. Do not conflate the two.
GH Secretagogues	Baseline GH is higher in premenopausal women. Research protocols should account for this when designing dosing schedules and measuring outcomes.
GLP-1 Agonists	Same dose protocols used in clinical trials. Side effect frequency may be higher in women. Rapid weight loss can temporarily affect menstrual cycles.
BPC-157	No sex-specific dosing differences identified in preclinical literature.
TB-500	No sex-specific dosing differences identified in preclinical literature.
GHK-Cu	No sex-specific differences. Plasma levels decline with age similarly in both sexes.

The Bottom Line

The premise of the question — “can women take the same peptides as men?” — is largely answered by the clinical trial record. Women made up the majority of GLP-1 trial participants. Tissue repair peptides like BPC-157 and TB-500 have no sex-specific mechanisms. GHK-Cu was developed partly for cosmetic and wound-healing applications that attract predominantly female research interest.

Where sex differences do matter, they are specific and knowable: PT-141 has different dosing profiles in women versus men. GH secretagogues operate against a higher baseline in premenopausal women. Rapid weight loss from GLP-1 agonists can temporarily disrupt menstrual cycling.

These are not reasons to avoid peptide research in women. They are reasons to design research protocols with appropriate sex-specific context.

Browse All Peptides →

References

1. Semaglutide in Obesity: Unmet Needs in Men (2023). PMC9981825
2. Body weight reduction in women treated with tirzepatide by reproductive stage (2025). PMC12015656
3. Semaglutide adverse events: a gendered phenomenon (2025). PMC12033487
4. Sikiric P et al. BPC 157, Robert’s stomach cytoprotection. Curr Pharm Des. 2020. PMC7096228
5. Goldstein AL et al. Thymosin beta-4 and tissue repair. Trends Mol Med. 2005. PMC8228050
6. Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of GH secretion in adults. Endocr Rev. 1998. PMC2699646
7. Birzniece V et al. Estrogen effects on GH action. Front Horm Res. 2013. PMC3765363
8. Clayton AH et al. Bremelanotide for female sexual dysfunctions in premenopausal women (2019). PMC6713510
9. GLP-1 receptor agonists during pregnancy and lactation (2024). PMC11649328

For laboratory and research use only. Not for human consumption. Not medical advice.